DreaMed Diabetes is dedicated to enhancing the lives of insulin-dependent patients and their caregivers, empowering them with innovative personalized medicine and decision support technology.
The company was established in 2014, as a spin-off the DREAM International Consortium, to commercialize the insulin control technology behind Glucositter. DreaMed Diabetes then innovated with artificial pancreas studies at patients’ homes, after which it became the first company in the world to receive a CE Mark approval for an artificial pancreas system.
In developing the adaptive MD Logic cognitive technology that underpins Advisor and Glucositter, DreaMed Diabetes managed and operated multicenter, multinational, large-scale clinical trials (full results were published in well-known healthcare journals). DreaMed Diabetes’ Advisor is currently in use in leading clinical centers in the European Union and the United States, where its safety and efficacy has been clearly demonstrated.